Apobec sbs13 mutational signature—a novel predictor of radioactive iodine refractory papillary thyroid carcinoma

HIGHLIGHTS

  • who: Sarah Siraj and colleagues from the Department of Pediatric Hematology-Oncology, King Faisal Specialist Hospital and Research Center have published the paper: APOBEC SBS13 Mutational Signature—A Novel Predictor of Radioactive Iodine Refractory Papillary Thyroid Carcinoma, in the Journal: Cancers 2022, 1584 of 15/03/2022
  • what: Since only SBS13 and TERTp were found to be positive predictors of RAI refractoriness, the authors focused on testing their ability alone or in combination to predict RAI refractoriness.
  • how: 3 of 15 This study was conducted in accordance with the Declaration of Helsinki and . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?